These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 8969327)

  • 21. Drug therapy: safety, effectiveness, and economics.
    Brandys J
    Przegl Lek; 2001; 58(4):226-8. PubMed ID: 11450340
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The economics of drug discovery and the ultimate valuation of pharmacotherapies in the marketplace.
    Sollano JA; Kirsch JM; Bala MV; Chambers MG; Harpole LH
    Clin Pharmacol Ther; 2008 Aug; 84(2):263-6. PubMed ID: 18547999
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The power of pharmacoeconomics.
    Healthc Exec; 2000; 15(1):44-5. PubMed ID: 11067028
    [No Abstract]   [Full Text] [Related]  

  • 24. Health economics--what the nephrologist should know.
    Palmer AJ
    Nephrol Dial Transplant; 2005 Jun; 20(6):1038-41. PubMed ID: 15840678
    [No Abstract]   [Full Text] [Related]  

  • 25. [Economic evaluation of drugs. Effectiveness in diabetes therapy].
    Schöffski O
    Dtsch Med Wochenschr; 2008 Aug; 133 Suppl 4():S106-9; discussion S124-6. PubMed ID: 18686218
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Harnessing economic drivers for successful clinical implementation of pharmacogenetic testing.
    Deverka PA; McLeod HL
    Clin Pharmacol Ther; 2008 Aug; 84(2):191-3. PubMed ID: 18679180
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacoeconomics: determining the value of drug therapy.
    Peterson C
    Healthplan; 1998; 39(3):44-50. PubMed ID: 10181751
    [No Abstract]   [Full Text] [Related]  

  • 28. Evaluating the quality of published pharmacoeconomic evaluations.
    Sanchez LA
    Hosp Pharm; 1995 Feb; 30(2):146-8, 151-2. PubMed ID: 10140528
    [No Abstract]   [Full Text] [Related]  

  • 29. A proposed model for conducting institutional-specific cost-effectiveness analysis: a case study of lipid-lowering agents.
    Hakim Z; Pierson JF; Pathak DS
    Pharm Pract Manag Q; 1996 Apr; 16(1):79-97. PubMed ID: 10157744
    [No Abstract]   [Full Text] [Related]  

  • 30. Considerations in the pharmacoeconomics of glaucoma.
    Hirsch JD
    Manag Care; 2002 Nov; 11(11 Suppl):32-7. PubMed ID: 15357537
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacoeconomics in the era of individualized medicine.
    Waldman SA; Terzic A
    Clin Pharmacol Ther; 2008 Aug; 84(2):179-82. PubMed ID: 18679176
    [No Abstract]   [Full Text] [Related]  

  • 32. Standards and certification to recognize pharmacoeconomics as a profession.
    Lyles A
    Clin Ther; 2003 Mar; 25(3):1004-6. PubMed ID: 12852714
    [No Abstract]   [Full Text] [Related]  

  • 33. Advanced purchase commitments for a malaria vaccine.
    Natl Bur Econ Res Bull Aging Health; 2005; (12):1-2. PubMed ID: 16175672
    [No Abstract]   [Full Text] [Related]  

  • 34. Managed care guidelines for the economic evaluation of pharmaceuticals.
    Langley PC; Martin RE
    Am J Manag Care; 1997 Jul; 3(7):1013-21. PubMed ID: 10173366
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Health utility elicitation: is there still a role for direct methods?
    Prosser LA; Grosse SD; Wittenberg E
    Pharmacoeconomics; 2012 Feb; 30(2):83-6. PubMed ID: 22185185
    [No Abstract]   [Full Text] [Related]  

  • 36. Pharmacoeconomics of subcutaneous allergen immunotherapy.
    Incorvaia C; Agostinis F; Amoroso S; Ariano R; Barbato A; Bassi M; Cadario G; Campi P; Cardinale F; Romano C; Ciprandi G; D'Anneo R; Dal Bo S; Di Gioacchino M; Fiocchi A; Galimberti M; Galli E; Giovannini M; La Grutta S; Lombardi C; Marcucci F; Marseglia GL; Mastrandrea F; Minelli M; Nettis E; Novembre E; Ortolani C; Pajno G; Piras PP; Passalacqua G; Patriarca G; Pucci S; Quercia O; Romano A; Schiavino D; Sforza M; Tosca MA; Tripodi S; Zambito M; Puccinelli P; Frati F
    Eur Ann Allergy Clin Immunol; 2007; 39 Spec No():17-20. PubMed ID: 18924462
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Pharmacoeconomics--survey and status].
    Pedersen KM
    Ugeskr Laeger; 2003 Apr; 165(16):1670-4. PubMed ID: 12756827
    [TBL] [Abstract][Full Text] [Related]  

  • 38. When will the U.S. flinch at cancer drug prices?
    Vanchieri C
    J Natl Cancer Inst; 2005 May; 97(9):624-6. PubMed ID: 15870428
    [No Abstract]   [Full Text] [Related]  

  • 39. Drugs take the spotlight in steering clinical, economic direction for ESRD.
    Neumann ME
    Nephrol News Issues; 2004 Jun; 18(7):50-1. PubMed ID: 15232997
    [No Abstract]   [Full Text] [Related]  

  • 40. The challenge of integrating monoclonal antibodies into the current healthcare system.
    Brixner DI; Bull SA
    Am J Manag Care; 1997 Jun; 3(6):903-11. PubMed ID: 10170294
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.